LONDON – Immuno-oncology specialist Tusk Therapeutics Ltd. is being acquired by Roche Holding AG for €70 million (US$81.3 million) up front, with €585 million to come if the sole product, an anti-CD25 antibody, currently in the late stages of preclinical development, makes it through to approval.